Market Feedback

Report
June 2023

© 2022. All rights reserved. IQVIA® is a registered trademark of IQVIA Inc. in the United States, the European Union, and various other countries.
 IPM Key Highlights – June’23
IPM Growth and Monthly Sale Trend
18,000 30
23.9
19.1
20
13.2 14.5
12.7
11.3 11.3
8.1 9.7 10.6
7.9 10
6.6 6.0 6.7
5.2 9.6
9…
8.3 7.7 7.1 6.2 6.5
6.2 4.5
3.0 3.5
15,000 0

-10

-20
June'22 15,687.4

July'22 16,626.6

Aug'22 17,574.7

Sept'22 17,571.7

Oct'22 16,241.8

Nov'22 17,317.6

Dec'22 17,097.4

Jan'23 16,572.9

Feb'23 16,657.1

Mar'23 17,106.7

Apr'23 17,798.9

June'23 16,468.8
May'23 17,114.7
12,000 -30

Month Value'Cr Month growth MAT growth

• IPM reported a lower growth of 4.5% for the month of

June’23. MAT growth declined to 10.6% for June’23.

Acute vs. Chronic Trend

220,000 70%

200,000 60%

180,000 50%
14.8%

160,000 10.6% 40%

10.5%
140,000 8.4% 30%
13.0% 7.1% 12.4%
120,000 10.4% 9.1% 20%
12.1%
9.1% 16.2% 8.0%
100,000 5.1% 10%
9.7%

80,000 0%

60,000 -10%
204744.6
139047.7

148858.2

107703.4

170895.5

185199.4

127517.4
116281.6
88139.6

50908.1

92650.5

56207.7

63192.1

68917.7

77227.2

40,000 -20%

20,000 -30%
MAT June'19 MAT June'20 MAT June'21 MAT June'22 MAT June'23
ACUTE CHRONIC OVERALL Acute growth Chronic Growth Overall Growth

• Chronic segment growth was higher at 12.1% as compared

to acute segment growth at 9.7% for MAT June’23.

Source: IQVIA TSA Dataset June'2023 1

 Monthly Growth Trends –
June’23
IPM June month growth trend as compared to
preceding May month
15%
12.8%

10% 9.6%

4.9%
5%
1.4% 0.9%
0.1%
0%

-2.7%
-5% -3.8% -3.7% -3.8%
-4.3%
-5.2%

-10%
-10.0%

-15%
-16.6%

-20% -20.2%

-25%
June'19 June'20 June'21 June'22 June'23
Acute Chronic Overall

In last five years, June month sale has always been lower than
preceding May month. The only exception was June’20 when
acute segment recovered from lock down restrictions.
IPM June month growth trend as compared to
June month of previous year

20,000.0 20.0%
15.7%
13.8%
12.8% 12.5%
18,000.0 13.8%
9.3% 13.4%
13.7% 7.7% 10.0%
6.3% 9.9%
16,000.0
7.3% 4.5%

14,000.0 2.7% 2.5% 0.0%

12,000.0

-10.0%
10,000.0

8,000.0 -20.0%

6,000.0

-30.0%
11489.5

12217.2

13853.5

15759.9

10026.7

16468.8

4,000.0
7234.4

4255.1

7429.1

4788.1

8593.6

5259.8

9778.2

5981.7

6442.2

2,000.0 -40.0%
June'19 June'20 June'21 June'22 June'23
Acute Chronic Overall Acute Growth Chronic Growth Overall Growth

For the month of June’23 as compared to June’22, Acute

segment grew by just 2.5% while Chronic segment grew by
7.7% resulting in overall growth of 4.5%.

Source: IQVIA TSA Dataset June'2023 2

Top Companies in IPM –June’23
RANKING MONTH June'23 MAT June'23
CORPORATIONS Values In Growth Values In Growth
MAT MON MS % MS % EVOL
Cr % Cr %

IPM 16468.82 100 4.50 204744.59 100 10.55 100

1 1 SUN* 1304.92 7.92 5.98 15714.02 7.67 11.18 100.57
2 2 ABBOTT* 1055.72 6.41 5.60 12672.00 6.19 10.85 100.27
3 3 CIPLA 849.92 5.16 3.44 11120.98 5.43 12.35 101.63
4 4 MANKIND 702.25 4.26 3.92 9076.32 4.43 15.10 104.12
5 5 ALKEM* 644.95 3.92 2.26 8319.46 4.06 14.74 103.78
6 8 LUPIN LIMITED 571.89 3.47 3.04 7066.36 3.45 7.68 97.40
7 6 INTAS PHARMA* 601.59 3.65 9.73 7049.86 3.44 14.83 103.87
8 7 TORRENT PHARMA* 586.20 3.56 4.79 6917.49 3.38 11.60 100.95
9 9 MACLEODS PHARMA 524.30 3.18 6.92 6786.34 3.31 15.17 104.18
10 12 ARISTO PHARMA* 445.02 2.70 2.47 5963.15 2.91 10.57 100.02
11 11 ZYDUS CADILA* 464.24 2.82 4.86 5916.52 2.89 9.91 99.42
12 10 DR REDDYS LABS 470.08 2.85 3.19 5887.85 2.88 5.95 95.84
13 13 GLAXOSMITHKLINE* 373.05 2.27 -1.26 5178.61 2.53 8.46 98.11
14 15 EMCURE* 330.83 2.01 3.54 4168.31 2.04 8.11 97.79
15 16 GLENMARK PHARMA 317.33 1.93 6.35 4164.61 2.03 11.82 101.14
16 14 USV 339.41 2.06 7.27 3964.36 1.94 11.34 100.71
17 17 IPCA LABS 302.63 1.84 5.22 3791.48 1.85 13.29 102.48
18 18 MICRO LABS* 261.60 1.59 1.34 3411.29 1.67 7.19 96.95
19 20 PFIZER* 238.61 1.45 -9.93 3291.40 1.61 0.00 90.45
20 19 SANOFI* 255.63 1.55 -0.88 3158.37 1.54 1.16 91.50
21 21 ALEMBIC 227.16 1.38 3.57 3118.81 1.52 11.81 101.13
22 23 FDC 179.39 1.09 7.62 2158.15 1.05 16.76 105.61
23 22 ERIS LIFESCIENCES* 182.53 1.11 5.52 2154.77 1.05 7.94 97.63
24 24 JB PHARMA* 178.90 1.09 11.18 2088.49 1.02 20.72 109.20
25 25 HIMALAYA DRUG 132.24 0.80 -6.83 1639.74 0.80 3.56 93.67
26 26 AJANTA PHARMA 131.50 0.80 10.38 1542.06 0.75 14.94 103.96
27 27 CADILA PHARMA 123.03 0.75 -0.22 1538.60 0.75 6.70 96.51
28 29 FRANCO INDIAN 101.12 0.61 -9.46 1449.00 0.71 7.70 97.42
29 28 LA RENON HEALTHCA. 122.24 0.74 28.19 1315.44 0.64 26.55 114.47
30 31 INDOCO* 96.10 0.58 -4.34 1286.46 0.63 5.09 95.06
31 33 BLUE CROSS 89.25 0.54 -1.82 1243.38 0.61 8.59 98.22
32 34 PROC.&GAMB.HEALTH 87.17 0.53 -4.69 1138.83 0.56 5.17 95.13
33 32 HETERO HEALTHCARE* 94.54 0.57 23.32 1135.13 0.55 17.30 106.10
34 30 CORONA REMEDIES 100.65 0.61 19.11 1134.75 0.55 20.54 109.03
35 35 SYSTOPIC 85.97 0.52 6.54 1016.89 0.50 8.48 98.12
36 36 MEDLEY PHARMA 83.92 0.51 -3.78 998.14 0.49 4.92 94.91
37 37 WIN MEDICARE 71.13 0.43 -0.68 916.55 0.45 10.89 100.30
38 38 HEGDE & HEGDE 70.25 0.43 -0.16 891.52 0.44 7.36 97.11
39 40 FOURRTS INDIA 66.70 0.41 8.73 846.94 0.41 12.34 101.61
40 46 APEX 59.97 0.36 -5.52 834.84 0.41 9.80 99.32

Source: IQVIA TSA Dataset June'2023 3

Top Brands in IPM – June’23
RANKINGS MONTH June'23 MAT June'23
MANU
PRODUCTS
(Abbr.) Values In Growth Values In Growth
MAT MON MS % MS % EVOL
Cr % Cr %
IPM 16468.82 100 4.50 204744.59 100 10.55 100
1 1 MIXTARD ABT 73.91 0.45 2.93 877.46 0.43 3.80 93.89
2 5 AUGMENTIN GSK 47.26 0.29 0.41 808.97 0.40 34.61 121.76
3 2 GLYCOMET-GP USV 69.23 0.42 8.21 796.63 0.39 15.48 104.46
4 3 FORACORT CPL 62.69 0.38 13.44 760.38 0.37 26.66 114.57
5 16 CLAVAM A.K 37.35 0.23 4.61 612.54 0.30 28.49 116.23
6 17 MONOCEF ATP 36.52 0.22 -8.87 605.26 0.30 6.61 96.43
7 18 LANTUS S.A 36.42 0.22 -30.38 594.78 0.29 -5.54 85.45
8 4 THYRONORM ABT 52.61 0.32 13.87 586.22 0.29 20.69 109.17
9 6 PAN A.K 46.98 0.29 1.15 556.98 0.27 15.32 104.31
10 15 BETADINE WMC 39.45 0.24 -6.91 548.08 0.27 13.27 102.45
11 9 LIV-52 HIM 43.46 0.26 -14.55 534.33 0.26 4.02 94.09
12 37 CALPOL GSK 27.09 0.16 -9.85 489.59 0.24 8.24 97.91
13 49 AZITHRAL AMB 23.88 0.15 -8.52 476.16 0.23 14.24 103.34
14 11 UDILIV SVY 40.60 0.25 10.85 475.46 0.23 17.97 106.71
15 7 RYZODEG ABT 45.40 0.28 31.78 474.60 0.23 36.06 123.07
16 10 PAN-D A.K 43.24 0.26 10.40 474.40 0.23 16.27 105.17
17 31 DUOLIN CPL 29.76 0.18 4.46 466.60 0.23 22.21 110.55
18 12 DEXORANGE F-I 39.81 0.24 -5.75 461.30 0.23 5.73 95.64
19 14 MANFORCE MA& 39.50 0.24 21.58 457.41 0.22 44.42 130.64
20 13 ZERODOL-SP IPC 39.50 0.24 13.77 456.15 0.22 21.69 110.08
21 39 DOLO MRB 26.64 0.16 12.87 455.03 0.22 15.91 104.85
22 21 NOVOMIX ABT 33.95 0.21 -11.07 433.82 0.21 -4.68 86.22
23 47 BUDECORT CPL 24.93 0.15 -4.93 428.70 0.21 41.90 128.35
24 19 SHELCAL TNT 36.05 0.22 -2.65 423.53 0.21 12.00 101.31
25 20 TELMA GMK 34.19 0.21 10.06 414.63 0.20 11.80 101.13
26 8 ELECTRAL FC8 44.36 0.27 38.68 413.01 0.20 24.68 112.78
27 24 ULTRACET JAN 33.22 0.20 0.26 401.57 0.20 10.98 100.39
28 22 ACILOC CI6 33.59 0.20 4.94 399.75 0.20 19.99 108.54
29 27 T-BACT GSK 31.49 0.19 21.87 388.46 0.19 30.30 117.86
30 23 ROSUVAS RBY 33.28 0.20 20.33 372.70 0.18 21.76 110.14
31 26 DUPHASTON SVY 31.83 0.19 -5.17 370.35 0.18 8.04 97.73
32 28 LEVIPIL SPI 31.21 0.19 6.87 369.26 0.18 7.55 97.28
33 62 MOXIKIND-CV MA& 21.28 0.13 5.09 363.49 0.18 35.08 122.18
34 29 ECOSPRIN-AV USV 30.98 0.19 16.13 360.56 0.18 23.64 111.84
35 32 RANTAC JBH 28.53 0.17 -3.44 356.74 0.17 18.71 107.38
36 50 ZIFI FC8 23.86 0.14 -10.06 353.32 0.17 14.77 103.81
37 38 MIKACIN ATP 26.95 0.16 -11.19 350.95 0.17 11.15 100.54
38 34 JANUMET MSD 27.88 0.17 -13.96 348.69 0.17 -16.83 75.23
39 30 VOLINI RG. 29.92 0.18 2.67 345.21 0.17 -1.96 88.68
40 25 CILACAR JBH 32.45 0.20 25.69 342.67 0.17 22.47 110.78

Source: IQVIA TSA Dataset June'2023 4

Top Therapeutic Class and
Indian Vs MNC Trend - June’23
Growth Growth
Rank Rank Value 'Cr MS% Value 'Cr MS%
% %
MAT MON
IPM 16468.8 100.0% 4.5% 204744.6 100.0% 10.6%
1 1 CARDIAC 2107.3 12.8% 8.5% 24920.9 12.2% 11.1%
2 3 ANTI-INFECTIVES 1590.3 9.7% -1.7% 23762.5 11.6% 14.0%
3 2 GASTRO INTESTINAL 1865.2 11.3% 3.3% 21571.9 10.5% 9.9%
4 4 ANTI DIABETIC 1577.3 9.6% 5.7% 18440.0 9.0% 7.5%
5 9 RESPIRATORY 1010.3 6.1% -5.6% 17770.2 8.7% 13.5%
6 6 PAIN / ANALGESICS 1322.4 8.0% 4.8% 16291.1 8.0% 12.4%
7 5 VITAMINS/MINERALS/NUTRIENTS 1361.1 8.3% 3.6% 15741.5 7.7% 7.3%
8 7 DERMA 1183.1 7.2% 7.6% 14184.3 6.9% 7.5%
9 8 NEURO / CNS 1030.5 6.3% 6.2% 12296.8 6.0% 10.6%
10 10 GYNAEC. 910.2 5.5% 4.3% 10416.8 5.1% 11.0%
11 11 ANTINEOPLAST/IMMUNOMODULATOR 403.6 2.5% 14.9% 4506.9 2.2% 23.1%
12 12 UROLOGY 362.1 2.2% 12.3% 4098.8 2.0% 15.3%
13 13 OPHTHAL / OTOLOGICALS 347.0 2.1% 8.1% 4046.7 2.0% 12.2%
14 14 HORMONES 253.5 1.5% 6.8% 3204.9 1.6% 13.9%
15 15 VACCINES 249.2 1.5% 9.7% 2800.4 1.4% -3.3%
16 16 HEPATOPROTECTIVES 194.3 1.2% 1.3% 2277.1 1.1% 8.7%
17 17 BLOOD RELATED 156.6 1.0% 6.6% 1820.4 0.9% 6.8%
18 18 STOMATOLOGICALS 137.0 0.8% 7.5% 1583.1 0.8% 16.8%
19 19 ANTIVIRAL 99.0 0.6% 21.0% 1127.8 0.6% -10.2%
20 21 ANTI-PARASITIC 46.6 0.3% -4.4% 572.3 0.3% 7.9%

• Anti-Viral, Antineoplast/immunomodulator, Urology and

Vaccines were the fastest growing therapies for the month of
June’23 as compared to June’22.
• Anti-Infective and Respiratory segments reported a
degrowth, pulling the monthly growth down for June’23.

• The ap between Indian companies and MNC companies

increased in the acute segment while it reduced in chronic
segment for MAT June’23 as compared to MAT June’22. At
overall level, the gap is almost steady at around 4%.

Source: IQVIA TSA Dataset June'2023 5

Top NI in IPM last 12 months
MAT
Rank BRANDS COMPANY SUPERGROUP
May'23'Cr

TOTAL NI VALUE 1684.4

1 COSVATE-GM ++ ERIS LIFESCIENCES* DERMA 24.6

2 ISTAVEL D SUN* ANTI DIABETIC 20.7

3 DYDROHOPE CORONA REMEDIES GYNAEC. 19.8

4 DAPANORM TRIO ALKEM* ANTI DIABETIC 18.6

5 KERENDIA BAYER ZYDUS PHARMA CARDIAC 18.3

6 OXRA-S SUN* ANTI DIABETIC 17.3

7 DENOSUREL RELIANCE LIFESCIE. PAIN / ANALGESICS 16.4

8 MAXICEF-O ARISTO PHARMA* ANTI-INFECTIVES 16.1

9 GLUXIT-S ERIS LIFESCIENCES* ANTI DIABETIC 14.9

10 SITARA-M INTAS PHARMA* ANTI DIABETIC 12.1

11 ALSITA-M ALKEM* ANTI DIABETIC 12.0

12 POLYBION A PROC.&GAMB.HEALTH VITAMINS/MINERALS/NUTRIENTS 11.9

13 UDAPA-S USV ANTI DIABETIC 11.2

14 CAVIM GUFIC ANTI-INFECTIVES 11.1

15 SITAXA D TORRENT PHARMA* ANTI DIABETIC 10.5

16 BONYDIL AR EX VITAMINS/MINERALS/NUTRIENTS 10.2

17 VALENTAS LUPIN LIMITED CARDIAC 10.1

18 ISTAMET D SUN* ANTI DIABETIC 10.0

19 SITAHENZ-M LA RENON HEALTHCA. ANTI DIABETIC 9.7

20 VERQUVO BAYER ZYDUS PHARMA CARDIAC 9.5

• 4551 brands were launched in last 12 months clocking a

sale of 1684.4 Cr, which is higher than last month.
• Brands launched in last 12 months contributed 0.8% to
IPM and 8.5% to MAT growth.
• Intas Pharma grossed the highest sales of 96.05 Cr from
40 brands, followed by Torrent @94.6 Cr from 36 brands,
and Eris @93.41 Cr from 31 brands.
• By value, Anti-Diabetic contribute 34.2% to the total NI
Value of 1684.4 Cr, followed by 8.8% contributed by
Gynaec. and 8.4% by Cardiology segment.
• Most number of 609 brands were launched in
Vitamins/Minerals/Nutrients segment.

Source: IQVIA TSA Dataset June'2023 6

Zonal fastest growing among
the Top 50 companies- MAT
June’23
Fastest Growing West Zone Fastest Growing South Zone
Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 JB PHARMA* 68.2 22 % HETERO HEALTHCARE* 107.4 42 %
2 CORONA REMEDIES 88.5 20 % EAST WEST PHARMA 58.8 42 %
3 SAMARTH PHARMA 27.7 19 % LA RENON HEALTHCA. 89.8 31 %
4 LA RENON HEALTHCA. 48.5 18 % ASTRAZENECA 51.1 29 %
5 INTAS PHARMA* 207.2 16 % MERCK SPECIALITIES 40.8 24 %
6 MANKIND 266.5 15 % RELIANCE LIFESCIE. 37.5 23 %
7 PROC.&GAMB.HEALTH 26.7 15 % ALKEM* 269.4 21 %
8 ALKEM* 167.1 14 % ARISTO PHARMA* 203.3 20 %
9 ABBOTT* 316.8 14 % MACLEODS PHARMA 201.5 20 %
10 FDC 98.3 13 % ALEMBIC 106.7 20 %
11 MACLEODS PHARMA 156.9 13 % JB PHARMA* 97.1 20 %
12 MICRO LABS* 31.6 13 % FDC 38.0 19 %
13 APEX 16.9 12 % IPCA LABS 122.6 17 %
14 ARISTO PHARMA* 101.2 11 % AJANTA PHARMA 54.5 16 %
15 AKUMENTIS HEALTH 16.0 10 % INTAS PHARMA* 203.8 15 %
16 AJANTA PHARMA 30.7 10 % MANKIND 259.4 14 %
17 U S V 78.9 9% BIOCON 27.0 14 %
18 FRANCO INDIAN 27.8 9% USV 185.4 13 %
19 WIN MEDICARE 14.3 9% FOURRTS INDIA 52.1 13 %
20 ZYDUS CADILA* 97.9 9% CIPLA 308.6 12 %

Fastest Growing North Zone Fastest Growing East Zone

Rank
Corporation Values'Cr Growth % Corporation Values'Cr Growth %
1 ASTRAZENECA 50.1 37 % LA RENON HEALTHCA. 71.7 31 %
2 SAMARTH PHARMA 44.9 30 % FDC 56.4 29 %
3 LA RENON HEALTHCA. 66.0 26 % CORONA REMEDIES 40.0 28 %
4 MARTIN HARRIS 29.2 22 % JB PHARMA* 98.2 23 %
5 GLENMARK PHARMA 178.3 21 % MICRO LABS* 108.9 21 %
6 WOCKHARDT LTD* 25.6 20 % INTEGRACE HEALTH. 30.9 20 %
7 CORONA REMEDIES 39.6 19 % EAST INDIA 25.2 19 %
8 JB PHARMA* 95.0 19 % AKUMENTIS HEALTH 25.1 19 %
9 AJANTA PHARMA 53.7 19 % PHARMED 38.6 19 %
10 MACLEODS PHARMA 322.9 19 % HETERO HEALTHCARE* 27.8 18 %
11 RAPTAKOS BRETT 27.5 18 % INTAS PHARMA* 248.3 17 %
12 FDC 117.0 17 % CIPLA 257.6 17 %
13 MANKIND 445.5 16 % TORRENT PHARMA* 236.9 16 %
14 ALKEM* 248.6 15 % AJANTA PHARMA 61.5 15 %
15 IPCA LABS 155.0 15 % FOURRTS INDIA 21.6 15 %
16 BLUE CROSS 36.6 14 % SUN* 546.8 15 %
17 CIPLA 465.0 14 % MANKIND 219.5 14 %
18 TORRENT PHARMA* 208.8 13 % WIN MEDICARE 27.0 14 %
19 INTAS PHARMA* 251.0 13 % WALLACE* 39.2 14 %
20 CADILA PHARMA 67.1 13 % IPCA LABS 111.2 13 %

Source: IQVIA TSA Dataset June'2023

7
Regional Performance in IPM-
MAT June’23
Zone State Values Crores MS % Growth %

North UTTAR PRADESH 22,683.2 40 % 8%

DELHI 9,191.3 16 % 20 %
RAJASTHAN 8,776.4 16 % 11 %
PUNJAB 6,625.9 12 % 14 %
HARYANA 4,304.0 8% 14 %
JAMMU & KASHMIR 2,454.2 4% 12 %
UTTARAKHAND 1,503.2 3% 9%
HIMACHAL PRADESH 674.6 1% 18 %

North Subtotal 56,212.9 27 % 12 %

South KARNATAKA 12,164.2 22 % 13 %
TAMILNADU 10,337.0 19 % 8%
KERALA 10,257.3 19 % 10 %
TELANGANA 9,856.8 18 % 15 %
ANDHRA PRADESH 7,767.1 14 % 8%
CHENNAI 4,177.5 8% 8%

South Subtotal 54,559.9 27 % 11 %

East WEST BANGAL 13,381.1 27 % 15 %
BIHAR 10,857.4 22 % 8%
KOLKATA 7,175.5 14 % 9%
ASSAM 6,936.5 14 % 12 %
ORISSA 6,451.8 13 % 10 %
JHARKHAND 2,874.2 6% 11 %
CHATTISGARH 2,492.2 5% 5%

East Subtotal 50,168.8 25 % 11 %

West MAHARASHTRA 17,598.6 40 % 9%
MADHYA PRADESH 9,014.1 21 % 11 %
GUJARAT 8,726.3 20 % 11 %
MUMBAI 7,815.7 18 % 0%
GOA 648.2 1% 5%

West Subtotal 43,802.9 21 % 8%

IPM 204,744.6 100 % 11 %

• UP, Maharashtra and West Bengal are the largest Pharma

markets in India in the same order.
• Among the large markets, Delhi, West Bengal and
Telangana are the fastest growing states in IPM.

Source: IQVIA TSA Dataset June'2023 8

Performance of Top 30 Metros
in IPM – June’23
MAT June'22 MAT June'23 MAT June'22 MAT June'23

Rank Metro Rank Metro

Values Growth Values Growth Values Growth Values Growth
Crores % Crores % Crores % Crores %

1 DELHI 7,681 15.5 % 9,191 19.7 % 17 LUDHIANA 937 9.9 % 1,080 15.3 %

2 MUMBAI 7,799 2.7 % 7,816 0.2 % 18 KANPUR 994 7.5 % 1,075 8.2 %

3 CALCUTTA 6,585 9.8 % 7,176 9.0 % 19 INDORE 857 6.2 % 1,041 21.5 %

4 HYDERABAD 4,887 14.9 % 5,677 16.2 % 20 KOCHI 917 11.4 % 1,024 11.7 %

5 BANGALORE 3,829 12.4 % 4,577 19.5 % 21 VIJAYWADA 784 8.8 % 848 8.1 %

6 CHENNAI 3,864 13.4 % 4,177 8.1 % 22 BHOPAL 676 5.9 % 793 17.3 %

7 PUNE 2,176 2.4 % 2,539 16.7 % 23 MADURAI 736 22.0 % 786 6.9 %

8 LUCKNOW 2,320 8.7 % 2,463 6.2 % 24 VADODARA 661 -7.0 % 739 11.8 %

9 AHMEDABAD 1,917 4.2 % 2,172 13.3 % 25 NASIK 708 -4.5 % 708 -0.0 %

10 PATNA 1,619 11.9 % 1,847 14.1 % 26 MEERUT 591 15.9 % 654 10.8 %

11 JAIPUR 1,724 17.5 % 1,833 6.3 % 27 ALLAHABAD 618 7.8 % 651 5.3 %

12 AGRA 1,233 19.7 % 1,426 15.6 % 28 JABALPUR 616 9.3 % 642 4.3 %

13 VARANASI 1,350 19.6 % 1,369 1.4 % 29 VIZAG 540 3.7 % 576 6.6 %

14 NAGPUR 1,096 0.5 % 1,238 13.0 % 30 ASANSOL 358 10.8 % 393 9.8 %

15 COIMBATORE 1,039 7.1 % 1,183 13.9 % Grand Total 60,060 9.7 % 66,813 11.2 %

16 SURAT 949 8.2 % 1,118 17.8 %

• Top 30 cities by market size mentioned in the above table

grew faster @ 11.2% as compared to IPM growth of 10.6%
for MAT June’23.
• Top 30 metros in India contributed to 32.6% to IPM Sales for
MAT June’23. This is the same as reported last month.
• Indore, Delhi, Bangalore, Surat and Bhopal were the fastest
growing markets among the Top 30 metros for MAT
June’23. They were on top last month also.
• 16 out of 30 Top metros grew faster than IPM while
14 metros grew at par or slower than the IPM growth of
10.6% for MAT June’23.

Source: IQVIA TSA Dataset June'2023 9

 East Zone Top Companies- MAT
June’23
ASSAM Bihar
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 ALKEM* 450.7 15 % ALKEM* 1,110.5 4%
2 ABBOTT* 449.8 8% ARISTO PHARMA* 1,107.0 -1 %
3 ALEMBIC 425.3 11 % MACLEODS PHARMA 698.9 20 %
4 SUN* 425.1 10 % SUN* 611.7 15 %
5 LUPIN LIMITED 386.3 6% ABBOTT* 551.2 11 %
6 EMCURE* 251.3 11 % CIPLA 370.4 14 %
7 CIPLA 245.5 10 % LUPIN LIMITED 337.9 8%
8 DR REDDYS LABS 225.1 6% INTAS PHARMA* 337.9 12 %
9 INTAS PHARMA* 220.5 17 % MANKIND 328.0 8%
10 GLAXOSMITHKLINE* 197.0 7% ZYDUS CADILA* 268.9 9%
11 TORRENT PHARMA* 181.1 17 % GLAXOSMITHKLINE* 259.4 6%
12 MACLEODS PHARMA 178.6 17 % DR REDDYS LABS 258.2 1%
13 ZYDUS CADILA* 169.1 9% TORRENT PHARMA* 237.6 14 %
14 IPCA LABS 164.9 18 % MICRO LABS* 232.4 17 %
15 MANKIND 164.9 19 % ALEMBIC 226.3 3%
16 GLENMARK PHARMA 158.1 19 % FRANCO INDIAN 197.5 -4 %
17 ARISTO PHARMA* 113.3 16 % IPCA LABS 180.1 15 %
18 SANOFI* 107.3 4% CADILA PHARMA 165.4 11 %
19 USV 95.7 8% EMCURE* 161.4 11 %
20 LA RENON HEALTHCA. 91.8 40 % PFIZER* 150.6 -1 %
Chattisgarh Jharkhand
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 MANKIND 186.6 12 % ALKEM* 231.2 4%
2 ABBOTT* 163.9 9% ABBOTT* 184.3 12 %
3 SUN* 153.3 14 % MACLEODS PHARMA 182.4 15 %
4 MACLEODS PHARMA 120.5 18 % ARISTO PHARMA* 160.6 7%
5 LUPIN LIMITED 90.8 1% MANKIND 138.5 5%
6 ZYDUS CADILA* 89.7 6% SUN* 128.6 26 %
7 CIPLA 77.6 10 % CIPLA 111.6 10 %
8 ARISTO PHARMA* 69.0 -3 % LUPIN LIMITED 111.5 3%
9 GLAXOSMITHKLINE* 65.0 5% TORRENT PHARMA* 91.2 20 %
10 INTAS PHARMA* 61.0 2% DR REDDYS LABS 79.3 6%
11 ALKEM* 60.2 -2 % GLAXOSMITHKLINE* 68.3 7%
12 DR REDDYS LABS 57.9 -8 % IPCA LABS 64.6 9%
13 TORRENT PHARMA* 52.3 5% ALEMBIC 57.4 19 %
14 FDC 46.7 19 % INTAS PHARMA* 57.0 14 %
15 IPCA LABS 45.2 9% USV 49.4 9%
16 ERIS LIFESCIENCES* 39.3 15 % EMCURE* 44.3 23 %
17 EMCURE* 39.2 -3 % ZYDUS CADILA* 44.0 5%
18 PFIZER* 38.7 -10 % SANOFI* 42.5 5%
19 BAIDYANATH 35.9 -9 % GLENMARK PHARMA 41.7 -2 %
20 USV 35.8 7% MICRO LABS* 39.4 21 %
Orissa West Bengal Kolkata
Rank Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %
1 MANKIND 400.0 15 % SUN* 1,858.8 19 % SUN* 739.9 11 %
2 MACLEODS PHARMA 396.2 6% ALKEM* 945.8 23 % LUPIN LIMITED 411.2 5%
3 ABBOTT* 382.1 9% ABBOTT* 719.6 13 % INTAS PHARMA* 374.7 24 %
4 ALKEM* 372.9 19 % TORRENT PHARMA* 679.2 16 % ALKEM* 355.5 13 %
5 SUN* 323.1 5% CIPLA 539.2 23 % ABBOTT* 333.2 10 %
6 INTAS PHARMA* 304.1 18 % DR REDDYS LABS 497.7 11 % TORRENT PHARMA* 317.9 18 %
7 ARISTO PHARMA* 259.2 7% ZYDUS CADILA* 456.7 11 % CIPLA 260.5 20 %
8 CIPLA 209.2 15 % GLAXOSMITHKLINE* 449.5 20 % MACLEODS PHARMA 227.3 -8 %
9 DR REDDYS LABS 180.1 1% LUPIN LIMITED 434.4 14 % DR REDDYS LABS 226.1 -17 %
10 TORRENT PHARMA* 177.5 12 % INTAS PHARMA* 371.6 17 % GLENMARK PHARMA 216.0 11 %
11 ZYDUS CADILA* 177.4 23 % MACLEODS PHARMA 348.4 9% ZYDUS CADILA* 206.4 10 %
12 GLENMARK PHARMA 158.4 -0 % MANKIND 329.8 24 % MANKIND 192.1 16 %
13 LUPIN LIMITED 147.8 10 % GLENMARK PHARMA 295.2 17 % EMCURE* 187.9 -5 %
14 ALEMBIC 144.8 12 % ARISTO PHARMA* 287.9 15 % JB PHARMA* 158.4 24 %
15 U S V 135.3 13 % ALEMBIC 267.4 14 % IPCA LABS 146.8 3%
16 IPCA LABS 134.6 3% EMCURE* 260.8 10 % GLAXOSMITHKLINE* 135.6 36 %
17 EMCURE* 125.4 7% IPCA LABS 238.5 24 % USV 135.4 8%
18 MICRO LABS* 90.0 32 % PFIZER* 179.3 1% SANOFI* 123.7 -16 %
19 MEDLEY PHARMA 84.3 17 % JB PHARMA* 163.9 24 % AJANTA PHARMA 103.5 4%
20 ERIS LIFESCIENCES* 83.8 17 % WALLACE* 153.6 20 % PFIZER* 91.8 1%

Source: IQVIA TSA Dataset June'2023 10

East Zone Top Brands- MAT
June’23
Assam Bihar
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 PAN A.K 48.8 19 % MONOCEF ATP 101.4 -15 %
2 CLAVAM A.K 36.6 21 % CLAVAM A.K 95.3 13 %
3 LIV-52 HIM 36.2 2% ACILOC CI6 74.3 16 %
4 AZITHRAL AMB 33.8 3% MONTAZ ATP 72.5 23 %
5 UDILIV SVY 31.3 16 % XONE A.K 70.4 -13 %
6 PAN-D A.K 30.9 13 % PANTOP-D ATP 68.8 5%
7 MIXTARD ABT 28.4 -0 % DEXORANGE F-I 66.4 2%
8 TELLZY-AM AMB 27.2 17 % A TO Z NS A.K 59.5 -1 %
9 ELECTRAL FC8 26.6 48 % MIKACIN ATP 59.0 4%
10 LANTUS S.A 26.4 2% MONOCEF-SB ATP 58.9 -7 %
11 THYRONORM ABT 26.3 23 % AZITHRAL AMB 57.9 -6 %
12 BEVON ZTU 24.7 14 % GRILINCTUS F-I 49.8 -11 %
13 TAPAL MSN 23.1 >500% ELECTRAL FC8 46.8 49 %
14 BETADINE WMC 22.7 23 % ZERODOL-SP IPC 46.2 19 %
15 TELLZY AMB 22.4 10 % TRAXOL CACHET 46.1 -2 %
16 RABLET-D LU. 22.3 7% ODICEF GALPHA 44.9 -15 %
17 ZERODOL-SP IPC 21.9 20 % TAXIM-O A.K 43.3 -4 %
18 NOVOMIX ABT 21.5 -12 % LIV-52 HIM 43.2 6%
19 GLYCOMET-GP USV 21.5 37 % TRAXOL-S GALPHA 42.1 -9 %
20 SHELCAL TNT 21.4 17 % ODICEF-S CACHET 39.7 11 %
Chattisgarh Jharkhand
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 MANFORCE MA& 29.3 42 % BETADINE WMC 19.3 54 %
2 BETNOVATE-C GSK 11.6 5% CLAVAM A.K 19.3 22 %
3 BETADINE WMC 10.1 2% XONE A.K 18.8 5%
4 RYZODEG ABT 9.4 72 % MIXTARD ABT 17.5 15 %
5 AMLOKIND-AT MA& 9.1 40 % TAXIM-O A.K 16.4 25 %
6 MIXTARD ABT 8.9 5% MANFORCE MA& 15.0 78 %
7 GLYCOMET-GP USV 8.8 22 % ALBUREL REL 14.9 1%
8 DEXORANGE F-I 8.5 17 % ELECTRAL FC8 14.7 78 %
9 ZINCOVIT APX 8.2 27 % RYZODEG ABT 13.0 56 %
10 PANDERM ++ MA5 8.1 2% AZITHRAL AMB 12.8 13 %
11 ACILOC CI6 8.1 8% MIKACIN ATP 11.3 -4 %
12 ELECTRAL FC8 8.0 34 % THYROX MA5 10.6 19 %
13 PROTINEX N/I 7.9 4% PAN A.K 10.5 -3 %
14 PREVENAR-13 WYE 7.8 -11 % RAPITHER-AB IPC 10.3 2%
15 ZIFI FC8 7.7 12 % UDILIV SVY 10.1 24 %
16 MONOCEF ATP 7.6 -1 % NOVOMIX ABT 9.9 19 %
17 LANTUS S.A 7.5 -13 % MONTAZ ATP 9.6 29 %
18 LIV-52 HIM 7.4 2% XONE-XP A.K 9.6 20 %
19 MOXIKIND-CV MA& 7.0 12 % GLYCOMET-GP USV 9.4 16 %
20 AZITHRAL AMB 7.0 49 % ZERODOL-SP IPC 9.4 12 %
Orissa West Bengal Kolkata
Rank Value' Growth Value' Growth Value' Growth
Brand Company Brand Company Brand Company
Cr % Cr % Cr %
1 MIXTARD ABT 42.4 5 % PAN-D A.K 112.0 18 % PAN A.K 47.7 23 %
2 GLYCOMET-GP USV 39.4 15 % CLAVAM A.K 108.6 28 % PAN-D A.K 47.3 10 %
3 MANFORCE MA& 34.3 37 % PAN A.K 101.8 26 % RANTAC JBH 42.1 32 %
4 CLAVAM A.K 34.1 37 % CALPOL GSK 79.9 19 % TELMA GMK 38.0 26 %
5 PANTOP-D ATP 25.6 23 % AZITHRAL AMB 79.8 8% CILACAR JBH 32.5 8%
6 PAN A.K 25.4 45 % AUGMENTIN GSK 75.0 64 % BETADINE WMC 30.1 12 %
7 AZITHRAL AMB 23.6 -2 % MOXCLAV RXC 66.7 36 % RYZODEG ABT 27.6 14 %
8 ASCORIL-LS GMK 21.8 23 % T-BACT GSK 62.9 35 % JANUMET MSD 26.5 -11 %
9 ZERODOL-SP IPC 20.7 5% RANTAC JBH 58.1 15 % LANTUS S.A 26.4 -32 %
10 CYRA-D SY8 20.3 6% FORACORT CPL 53.1 52 % CLAVAM A.K 25.1 33 %
11 RAZO-D DRL 18.6 25 % OMEZ DRL 49.9 -2 % MIXTARD ABT 23.9 3%
12 CHERI IDH 17.6 8% PANTOCID-D SPI 43.9 20 % ROSUVAS RBY 23.3 18 %
13 UDILIV SVY 17.5 32 % DUOLIN CPL 43.9 15 % CILACAR-T JBH 22.7 27 %
14 RENERVE PLUS ELS 17.2 54 % VOLINI RG. 43.3 6% AUGMENTIN GSK 21.3 75 %
15 UNWANTED-KIT MA& 17.1 10 % SHELCAL TNT 42.2 22 % OMEZ DRL 21.1 -15 %
16 NOVOMIX ABT 17.1 -14 % TAXIM-O A.K 38.2 21 % GLUCONORM-G LU. 20.7 9%
17 O2 MY. 16.8 39 % UNIENZYME TNT 37.7 17 % SHELCAL TNT 20.5 26 %
18 MONTEK-LC SPI 16.4 9% ASCORIL-LS GMK 37.6 43 % DUPHALAC SVY 20.2 22 %
19 PANTOP ATP 16.3 9% ZERODOL-SP IPC 36.9 29 % GLYCOMET-GP USV 20.0 9%
20 FORACORT CPL 15.9 52 % ELTROXIN GSK 36.4 44 % FORACORT CPL 19.9 33 %

Source: IQVIA TSA Dataset June'2023 11

North Zone Top Companies-
MAT June’23
Delhi Haryana
Rank
Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 835.5 17 % CIPLA 512.2 19 %
2 ABBOTT* 628.3 19 % ABBOTT* 323.1 16 %
3 CIPLA 555.7 11 % SUN* 309.3 18 %
4 INTAS PHARMA* 532.9 27 % LUPIN LIMITED 205.0 12 %
5 TORRENT PHARMA* 412.6 27 % INTAS PHARMA* 197.6 10 %
6 LUPIN LIMITED 329.6 12 % MANKIND 166.8 20 %
7 SANOFI* 317.8 18 % ZYDUS CADILA* 152.0 8%
8 DR REDDYS LABS 317.2 14 % GLAXOSMITHKLINE* 129.8 6%
9 ZYDUS CADILA* 271.5 27 % TORRENT PHARMA* 115.5 17 %
10 ALKEM* 264.8 21 % MACLEODS PHARMA 109.0 18 %
11 GLAXOSMITHKLINE* 260.9 19 % DR REDDYS LABS 108.7 15 %
12 MANKIND 240.3 27 % USV 89.0 11 %
13 GLENMARK PHARMA 206.1 23 % GLENMARK PHARMA 86.9 25 %
14 JANSSEN 178.2 22 % ALKEM* 84.7 32 %
15 USV 169.1 18 % SANOFI* 74.2 11 %
16 EMCURE* 165.1 10 % IPCA LABS 72.6 11 %
17 MACLEODS PHARMA 141.6 15 % ARISTO PHARMA* 71.9 24 %
18 MICRO LABS* 139.7 47 % MICRO LABS* 69.4 24 %
19 BOEHRINGER INGELH. 130.4 22 % PFIZER* 68.8 3%
20 PFIZER* 123.2 6% FDC 58.0 25 %
Himachal Pradesh J&K Punjab
Rank Growth Growth Growth
Company Value'Cr Company Value'Cr Company Value'Cr
% % %
1 IPCA LABS 71.2 52 % SUN* 184.2 15 % CIPLA 662.8 15 %
2 CIPLA 64.6 7 % INTAS PHARMA* 182.5 14 % SUN* 480.2 12 %
3 INTAS PHARMA* 28.5 16 % CIPLA 147.3 8 % ABBOTT* 457.7 17 %
4 SUN* 28.3 18 % ABBOTT* 141.6 11 % MICRO LABS* 260.8 -21 %
5 ABBOTT* 28.2 21 % LUPIN LIMITED 118.4 14 % LUPIN LIMITED 237.7 25 %
6 MACLEODS PHARMA 27.6 33 % ARISTO PHARMA* 108.5 11 % GLAXOSMITHKLINE* 230.8 10 %
7 USV 25.4 11 % DR REDDYS LABS 97.5 22 % INTAS PHARMA* 210.8 10 %
8 MANKIND 22.0 8 % MACLEODS PHARMA 86.1 14 % MACLEODS PHARMA 200.7 28 %
9 LUPIN LIMITED 21.4 8 % ZYDUS CADILA* 74.2 15 % MANKIND 200.2 23 %
10 ZYDUS CADILA* 20.4 39 % GLAXOSMITHKLINE* 65.5 5 % TORRENT PHARMA* 194.5 21 %
11 ARISTO PHARMA* 19.5 20 % ERIS LIFESCIENCES* 64.5 15 % ZYDUS CADILA* 191.8 17 %
12 BDF 18.3 -22 % TORRENT PHARMA* 61.7 13 % PFIZER* 183.1 15 %
13 GLAXOSMITHKLINE* 18.0 16 % ALEMBIC 58.9 11 % GLENMARK PHARMA 147.1 18 %
14 EMCURE* 17.5 40 % GLENMARK PHARMA 58.1 22 % IPCA LABS 142.1 19 %
15 GLENMARK PHARMA 15.1 14 % IPCA LABS 55.9 10 % DR REDDYS LABS 139.6 28 %
16 TORRENT PHARMA* 14.8 20 % EMCURE* 52.2 10 % SANOFI* 124.6 7%
17 DABUR INDIA 9.7 4 % MANKIND 52.0 11 % U S V 122.2 13 %
18 P&G.HEALTH 9.5 36 % SANOFI* 48.2 18 % ARISTO PHARMA* 105.4 27 %
19 PFIZER* 8.6 0 % ALKEM* 44.5 8 % ALKEM* 97.6 17 %
20 INDOCO* 8.1 3 % MICRO LABS* 35.1 20 % AAREEN HEALTHCARE 93.8 60 %
Rajasthan Uttar Pradesh Uttarakhand
Rank Growth Growth Growth
Company Value'Cr Company Value'Cr Company Value'Cr
% % %
1 SUN* 722.4 11 % MANKIND 2,101.4 15 % MANKIND 92.0 14 %
2 CIPLA 544.4 13 % ABBOTT* 1,366.4 1% CIPLA 86.4 19 %
3 MACLEODS PHARMA 486.3 21 % CIPLA 1,316.0 13 % MACLEODS PHARMA 85.2 8%
4 ABBOTT* 461.9 11 % SUN* 1,042.8 7% SUN* 79.1 2%
5 INTAS PHARMA* 378.1 5% ALKEM* 1,037.8 11 % ABBOTT* 77.5 6%
6 TORRENT PHARMA* 353.3 10 % ARISTO PHARMA* 925.4 10 % LUPIN LIMITED 66.2 1%
7 MANKIND 327.5 16 % MACLEODS PHARMA 916.0 17 % MICRO LABS* 60.4 37 %
8 ALKEM* 326.1 18 % LUPIN LIMITED 776.8 9% GLAXOSMITHKLINE* 59.4 -0 %
9 ARISTO PHARMA* 305.0 7% GLAXOSMITHKLINE* 718.5 4% INTAS PHARMA* 51.6 7%
10 ZYDUS CADILA* 284.8 15 % ZYDUS CADILA* 664.4 3% IPCA LABS 47.7 28 %
11 LUPIN LIMITED 267.7 5% INTAS PHARMA* 639.8 9% ARISTO PHARMA* 47.2 9%
12 DR REDDYS LABS 250.8 8% TORRENT PHARMA* 566.8 6% GLENMARK PHARMA 46.6 22 %
13 GLAXOSMITHKLINE* 199.5 5% IPCA LABS 534.0 12 % ALKEM* 44.3 47 %
14 IPCA LABS 161.6 5% MICRO LABS* 481.5 1% TORRENT PHARMA* 37.4 1%
15 MICRO LABS* 134.0 11 % FDC 479.1 13 % ERIS LIFESCIENCES* 33.0 23 %
16 SANOFI* 132.1 13 % PFIZER* 451.2 9% DR REDDYS LABS 32.9 2%
17 GLENMARK PHARMA 130.2 26 % DR REDDYS LABS 444.8 -0 % HIMALAYA DRUG 29.0 9%
18 EMCURE* 125.0 4% SANOFI* 390.1 2% ZYDUS CADILA* 27.4 -17 %
19 PFIZER* 119.1 3% EMCURE* 365.9 15 % SANOFI* 26.0 1%
20 JB PHARMA* 103.3 21 % GLENMARK PHARMA 355.6 17 % USV 19.2 -1 %

Source: IQVIA TSA Dataset June'2023 12

North Zone Top Brands- MAT
June’23
Delhi Haryana Himachal Pradesh
Rank Value Growth Value' Growth Value' Growth
Brand Company Brand Company Brand Company
'Cr % Cr % Cr %
1 ULTRACET JAN 78.2 24 % FORACORT CPL 33.0 41 % HANSAPLAST BF5 18.3 -22 %
2 LANTUS S.A 63.7 6 % AUGMENTIN GSK 28.2 9 % ZERODOL-SP IPC 7.3 41 %
3 AUGMENTIN GSK 62.0 54 % LIV-52 HIM 22.6 11 % METPURE-XL EMC 5.1 47 %
4 VOLINI RG. 60.6 -1 % GLYCOMET-GP USV 18.1 10 % HCQS IPC 4.6 67 %
5 REVITAL H RG. 52.6 -20 % BUDECORT CPL 17.6 75 % ZERODOL-TH IPC 4.3 33 %
6 ZAXTER A.K 44.9 15 % UDILIV SVY 16.8 22 % ZERODOL-P IPC 3.6 84 %
7 UDILIV SVY 44.3 37 % RYZODEG ABT 16.5 22 % GLYCOMET-GP USV 3.5 28 %
8 REMICADE JAN 42.0 77 % MANFORCE MA& 16.3 26 % FORACORT CPL 3.4 13 %
9 LIV-52 HIM 40.5 18 % BETADINE WMC 15.9 16 % AUGMENTIN GSK 3.3 36 %
10 JARDIANCE B.I 40.3 28 % MONTAIR-LC CPL 15.9 31 % EVION PGH 3.3 78 %
11 THYRONORM ABT 40.2 66 % CEFTUM GSK 15.4 18 % JALRA-M USV 3.3 2%
12 BETADINE WMC 38.0 19 % DUOLIN CPL 15.3 36 % LIV-52 HIM 3.2 21 %
13 FORACORT CPL 35.8 38 % GLUCONORM-G LU. 14.9 11 % THYROX MA5 3.2 18 %
14 GLYXAMBI B.I 35.6 54 % ZIFI FC8 13.5 33 % FOLITRAX IPC 2.8 76 %
15 JANUMET MSD 35.3 -13 % MIXTARD ABT 13.2 -4 % MANFORCE MA& 2.7 31 %
16 INFLUVAC SVY 34.3 1 % MONOCEF ATP 12.1 27 % DUOLIN CPL 2.7 -11 %
17 EVION PGH 32.3 83 % LANTUS S.A 11.1 -1 % BECOSULES PFZ 2.7 4%
18 RYZODEG ABT 29.6 50 % ACILOC CI6 11.0 9 % BEVATAS IN9 2.6 4%
19 SHELCAL TNT 29.3 19 % BECOSULES PFZ 11.0 -11 % URIMAX-D CPL 2.5 -11 %
20 PREVENAR-13 WYE 28.3 6% ROSUVAS RBY 10.9 29 % SAAZ IPCA 2.4 69 %

J&K Punjab Rajasthan

Rank Value Growth Value' Growth Value Growth
Brand Company Brand Company Brand Company
'Cr % Cr % 'Cr %
1 AUGMENTIN GSK 16.7 1% AUGMENTIN GSK 39.3 31 % MONOCEF ATP 65.6 -12 %
2 HUMINSULIN LU. 15.7 3% FORACORT CPL 37.1 42 % FORACORT CPL 47.7 30 %
3 PANTOP ATP 15.0 11 % UDILIV SVY 36.9 18 % AUGMENTIN GSK 35.1 30 %
4 THYRONORM ABT 13.3 6% LIV-52 HIM 34.2 10 % MANFORCE MA& 32.9 55 %
5 UDILIV SVY 12.7 10 % BECOSULES PFZ 34.0 9 % LANTUS S.A 28.0 16 %
6 PANTOP-D ATP 12.0 -3 % MYHEP ALL MYL 31.5 6 % DEXORANGE F-I 26.6 13 %
7 MONOCEF-SB ATP 10.3 26 % COREX-DX PFZ 29.2 28 % AMICIN ZBC 25.6 5%
8 INFLUVAC SVY 10.0 22 % SUPRADYN BAYER 27.7 55 % MONTAIR-LC CPL 24.1 23 %
9 LANTUS S.A 9.4 2% MIXTARD ABT 25.5 2 % BETNOVATE-N GSK 23.5 -6 %
10 MONOCEF ATP 8.9 10 % BUDECORT CPL 24.9 36 % LIV-52 HIM 23.0 6%
11 MANFORCE MA& 7.8 38 % BECOZYM-C FORT BAYER 24.5 40 % PANTOCID-D SPI 21.9 22 %
12 URISPAS MH 7.8 12 % MONTAIR-LC CPL 23.6 1 % DUOLIN CPL 20.8 14 %
13 CYRA-D SY8 7.7 23 % GLYCOMET-GP USV 22.2 27 % GEMER SPI 20.0 24 %
14 DIGENE ABT 7.6 -6 % DYTOR CPL 21.4 24 % BETADINE WMC 19.4 4%
15 LEVERA IN9 7.6 14 % THYRONORM ABT 21.0 21 % MONOCEF-SB ATP 19.4 -2 %
16 TELMA-AM GMK 7.5 38 % ECOSPRIN-AV USV 20.2 24 % RANTAC JBH 19.3 22 %
17 DART JUG 7.5 41 % ACILOC CI6 19.9 34 % THYRONORM ABT 19.2 37 %
18 ROSUVAS RBY 7.4 41 % DUPHASTON SVY 19.8 11 % AEROCORT CPL 19.2 10 %
19 DROTIN M.H 6.8 34 % MANFORCE MA& 19.8 79 % LEVIPIL SPI 19.0 13 %
20 CALPOL GSK 6.7 44 % PREVENAR-13 WYE 19.1 13 % CALPOL GSK 19.0 10 %
Uttar Pradesh Uttarakhand
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 MONOCEF ATP 162.3 16 % AUGMENTIN GSK 12.8 12 %
2 UNWANTED-KIT MA& 139.8 31 % LIV-52 HIM 12.1 -1 %
3 ACILOC CI6 124.6 39 % BETADINE WMC 9.0 27 %
4 LIV-52 HIM 119.6 -7 % MANFORCE MA& 7.8 39 %
5 MANFORCE MA& 119.6 40 % FORACORT CPL 6.3 29 %
6 PHENSEDYL COUGH A1H 110.0 -42 % DOLO MRB 6.2 91 %
7 ZIFI FC8 109.5 12 % ACILOC CI6 5.6 24 %
8 DEXORANGE F-I 104.9 5% CALPOL GSK 5.4 21 %
9 AUGMENTIN GSK 102.4 30 % BETNOVATE-N GSK 5.3 -14 %
10 FORACORT CPL 98.5 29 % MONOCEF ATP 5.1 26 %
11 MOXIKIND-CV MA& 93.7 35 % LANTUS S.A 4.8 -11 %
12 CALPOL GSK 92.6 -5 % JANUMET MSD 4.7 -25 %
13 MIKACIN ATP 88.3 0% LEVERA IN9 4.7 15 %
14 BETADINE WMC 83.8 9% SIMILAC ABT 4.6 22 %
15 ELECTRAL FC8 83.2 8% GLIMISAVE MV ELS 4.1 40 %
16 ZERODOL-SP IPC 80.3 21 % THYRONORM ABT 4.1 24 %
17 BETNOVATE-N GSK 74.5 4% ZERODOL-SP IPC 4.0 13 %
18 CODISTAR MA& 69.8 3% GLYCOMET-GP USV 3.9 11 %
19 GUDCEF MA& 67.6 29 % TELMA-AM GMK 3.8 44 %
20 METROGYL JBH 65.1 9% URIMAX-D CPL 3.6 125 %

Source: IQVIA TSA Dataset June'2023 13

West Zone Top Companies-
MAT June’23
Goa Gujarat
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 48.7 6% CIPLA 584.4 12 %
2 ABBOTT* 37.7 -3 % ABBOTT* 564.0 12 %
3 ZYDUS CADILA* 32.9 -7 % SUN* 443.5 8%
4 CIPLA 32.0 3% TORRENT PHARMA* 433.7 15 %
5 TORRENT PHARMA* 30.6 14 % ZYDUS CADILA* 346.0 19 %
6 DR REDDYS LABS 28.5 17 % INTAS PHARMA* 331.0 17 %
7 GLAXOSMITHKLINE* 21.4 29 % MANKIND 324.6 15 %
8 LUPIN LIMITED 21.2 10 % UNISON PHARMA 273.2 5%
9 MANKIND 19.7 -14 % DR REDDYS LABS 210.2 7%
10 EMCURE* 19.2 16 % GLAXOSMITHKLINE* 196.6 10 %
11 PFIZER* 17.7 9% USV 187.6 17 %
12 INDOCO* 15.1 8% CORONA REMEDIES 187.1 23 %
13 MACLEODS PHARMA 14.1 -0 % LUPIN LIMITED 181.7 1%
14 ARISTO PHARMA* 14.1 22 % ALKEM* 179.2 20 %
15 ALEMBIC 13.6 15 % EMCURE* 167.4 11 %
16 GLENMARK PHARMA 12.3 7% MACLEODS PHARMA 160.6 14 %
17 USV 12.3 -15 % PFIZER* 157.1 -2 %
18 WALLACE* 10.6 17 % IPCA LABS 155.9 6%
19 ERIS LIFESCIENCES* 9.8 15 % ARISTO PHARMA* 154.2 15 %
20 CENTAUR 9.6 28 % SANOFI* 141.6 1%

Madhya Pradesh Maharashtra Mumbai

Rank Company Value'Cr Growth % Company Value'Cr Growth % Company Value'Cr Growth %
1 MANKIND 538.1 20 % CIPLA 1,050.5 15 % ABBOTT* 584.4 12 %
2 ABBOTT* 512.0 12 % ABBOTT* 931.4 18 % SUN* 567.0 2%
3 ARISTO PHARMA* 464.2 15 % SUN* 923.3 9% CIPLA 503.9 -6 %
4 SUN* 452.8 7% MANKIND 862.3 17 % INTAS PHARMA* 376.1 32 %
5 MACLEODS PHARMA 394.7 17 % EMCURE* 717.6 15 % TORRENT PHARMA* 344.2 -1 %
6 ALKEM* 323.7 16 % ALKEM* 642.0 17 % MANKIND 302.3 5%
7 LUPIN LIMITED 313.9 12 % MACLEODS PHARMA 624.6 9% EMCURE* 295.2 -5 %
8 CIPLA 303.8 8% DR REDDYS LABS 596.9 7% GLAXOSMITHKLINE* 245.8 7%
9 INTAS PHARMA* 292.5 7% TORRENT PHARMA* 504.5 9% PFIZER* 242.7 -9 %
10 ZYDUS CADILA* 267.1 11 % INTAS PHARMA* 504.2 11 % DR REDDYS LABS 240.8 2%
11 TORRENT PHARMA* 224.7 9% LUPIN LIMITED 502.0 3% USV 223.0 6%
12 DR REDDYS LABS 211.0 6% FDC 497.5 13 % GLENMARK PHARMA 218.1 -2 %
13 GLAXOSMITHKLINE* 195.5 10 % ZYDUS CADILA* 390.2 7% ALKEM* 208.7 7%
14 FDC 179.1 21 % USV 357.6 7% LUPIN LIMITED 202.0 -10 %
15 IPCA LABS 142.2 9% GLAXOSMITHKLINE* 345.6 1% MACLEODS PHARMA 186.7 19 %
16 EMCURE* 140.6 5% GLENMARK PHARMA 319.3 9% IPCA LABS 153.6 4%
17 ALEMBIC 133.8 18 % IPCA LABS 307.2 10 % ZYDUS CADILA* 131.9 -5 %
18 U S V 131.2 14 % ARISTO PHARMA* 296.0 7% SANOFI* 124.0 -37 %
19 SANOFI* 120.1 6% ALEMBIC 295.8 8% ERIS LIFESCIENCES* 94.2 -4 %
20 MEDLEY PHARMA 113.3 8% INDOCO* 262.4 4% NOVARTIS INTL.* 85.2 -5 %

Source: IQVIA TSA Dataset June'2023 14

West Zone Top Brands- MAT
June’23
Goa Gujarat Madhya Pradesh
Rank Value Growth Value' Growth Value Growth
Brand Company Brand Company Brand Company
'Cr % Cr % 'Cr %
1 DEXOLAC N/I 4.5 27 % FORACORT CPL 39.1 23 % MONOCEF ATP 55.2 29 %
2 AUGMENTIN GSK 4.0 40 % PREVENAR-13 WYE 37.3 -9 % DEXORANGE F-I 46.8 17 %
3 ELECTRAL FC8 3.1 52 % ZOSTUM ZTU 34.1 30 % ACILOC CI6 42.9 17 %
4 GELUSIL-MPS P.D 2.9 11 % VIVITRA ZYD 33.9 34 % MANFORCE MA& 40.2 50 %
5 BETADINE WMC 2.8 -8 % AUGMENTIN GSK 32.3 29 % ELECTRAL FC8 38.4 8%
6 LOSAR TNT 2.7 44 % ECOSPRIN-AV USV 31.0 33 % ZIFI FC8 29.7 27 %
7 SINAREST NEW CAU 2.7 15 % DUOLIN CPL 30.5 26 % MONTAZ ATP 29.6 14 %
8 MAGNEX PFZ 2.6 33 % LANTUS S.A 30.4 -9 % MIKACIN ATP 26.1 20 %
9 OROFER-XT EMU 2.4 132 % MIXTARD ABT 30.4 -7 % AUGMENTIN GSK 25.7 24 %
10 VOLINI RG. 2.4 -9 % GLYCOMET-GP USV 27.7 17 % LANTUS S.A 25.2 8%
11 CILACAR JBH 2.4 72 % INFLUVAC SVY 26.7 20 % ZINCOVIT APX 25.0 10 %
12 THROMBOPHOB ZYC 2.3 6% DUPHASTON SVY 26.1 1% GLYCOMET-GP USV 24.6 22 %
13 ATORVA ZYC 2.3 -18 % ALBUREL REL 25.7 10 % CALPOL GSK 24.5 11 %
14 SHELCAL TNT 2.0 -2 % BUDECORT CPL 25.6 69 % LIV-52 HIM 24.5 10 %
15 CEFTUM GSK 1.9 64 % THYRONORM ABT 25.1 20 % MONOCEF-O ATP 22.3 20 %
16 AZEE CPL 1.9 24 % ZIFI FC8 23.5 6% PANTOP ATP 21.6 12 %
17 GLYCOMET-GP USV 1.9 -21 % RYZODEG ABT 20.9 38 % PRACTIN DRL 21.5 2%
18 DOLO MRB 1.9 39 % MERO ATP 20.6 33 % TAXIM A.K 21.5 6%
19 COFSILS CIPLA 1.8 69 % INFANRIX HEXA GSK 19.8 13 % FORACORT CPL 20.6 20 %
20 ECONORM DRL 1.7 42 % IMMUNOREL REL 19.4 17 % MEGA-CV ATP 20.3 19 %

Maharashtra Mumbai
Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %
1 ENERZAL FC8 80.2 35 % AUGMENTIN GSK 55.7 45 %
2 HANSAPLAST BF5 77.6 34 % VYMADA SDZ 38.9 14 %
3 CLAVAM A.K 75.6 35 % FORACORT CPL 37.1 10 %
4 GLYCOMET-GP USV 67.0 15 % MIXTARD ABT 31.9 -5 %
5 FORACORT CPL 55.3 18 % MINIPRESS-XL PFZ 31.1 -7 %
6 MIXTARD ABT 52.2 9% ELIQUIS PFZ 30.9 -41 %
7 ZIFI FC8 51.1 0% RYZODEG ABT 30.5 44 %
8 AUGMENTIN GSK 49.5 32 % GLYCOMET-GP USV 30.2 12 %
9 ECOSPRIN-AV USV 49.3 20 % OROFER-XT EMU 27.9 2%
10 MOXIKIND-CV MA& 43.4 40 % SUPACEF GSK 27.6 15 %
11 DUOLIN CPL 43.0 33 % NOVOMIX ABT 27.5 -5 %
12 ELECTRAL FC8 41.5 14 % IMMUNOREL REL 27.4 -24 %
13 PAN A.K 39.5 20 % SHELCAL TNT 27.2 -6 %
14 MEROPLAN A1H 38.2 78 % BETADINE WMC 26.8 8%
15 BETADINE WMC 37.7 14 % TELMA GMK 26.5 -26 %
16 AZEE CPL 36.3 -5 % BECOSULES PFZ 25.9 4%
17 BUDECORT CPL 36.3 45 % LANTUS S.A 25.4 -42 %
18 DUPHASTON SVY 35.2 13 % CEFTUM GSK 25.4 22 %
19 SINAREST CAU 35.0 6% OROFER FCM EMU 23.7 -12 %
20 TELMA GMK 34.6 22 % NOVO RAPID ABT 23.5 2%

Source: IQVIA TSA Dataset June'2023 15

South Zone Top Companies-
MAT June’23
Andhra Pradesh Karnataka
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 771.9 4% SUN* 928.2 17 %
2 ABBOTT* 510.6 10 % ABBOTT* 743.6 18 %
3 MANKIND 416.8 10 % CIPLA 581.7 17 %
4 ARISTO PHARMA* 350.5 12 % MANKIND 559.3 20 %
5 CIPLA 335.5 6% MICRO LABS* 508.0 8%
6 ALKEM* 279.8 13 % USV 439.4 17 %
7 INTAS PHARMA* 272.4 15 % ALKEM* 422.3 18 %
8 LUPIN LIMITED 270.5 5% DR REDDYS LABS 406.0 10 %
9 MACLEODS PHARMA 268.0 20 % LUPIN LIMITED 370.3 5%
10 DR REDDYS LABS 256.4 5% ZYDUS CADILA* 346.8 8%
11 TORRENT PHARMA* 222.6 9% TORRENT PHARMA* 272.0 11 %
12 ZYDUS CADILA* 211.0 12 % GLAXOSMITHKLINE* 266.9 10 %
13 USV 201.9 14 % EMCURE* 250.8 6%
14 GLENMARK PHARMA 152.3 9% MACLEODS PHARMA 247.9 16 %
15 GLAXOSMITHKLINE* 126.2 5% INTAS PHARMA* 236.0 0%
16 EMCURE* 120.1 17 % GLENMARK PHARMA 233.9 6%
17 MICRO LABS* 107.0 1% ARISTO PHARMA* 186.5 19 %
18 PFIZER* 103.9 -2 % IPCA LABS 172.0 16 %
19 IPCA LABS 97.0 7% SANOFI* 170.7 23 %
20 BLUE CROSS 96.4 4% ALEMBIC 148.1 27 %
Kerala Tamilnadu
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 SUN* 1,346.6 12 % SUN* 1,225.1 6%
2 ABBOTT* 763.8 7% CIPLA 713.1 11 %
3 CIPLA 715.8 11 % ABBOTT* 703.2 8%
4 TORRENT PHARMA* 540.8 7% TORRENT PHARMA* 471.4 7%
5 ZYDUS CADILA* 450.9 9% MANKIND 414.2 10 %
6 LUPIN LIMITED 331.5 4% LUPIN LIMITED 380.4 9%
7 MACLEODS PHARMA 287.9 19 % ZYDUS CADILA* 328.8 0%
8 INTAS PHARMA* 284.4 13 % GLAXOSMITHKLINE* 316.3 10 %
9 DR REDDYS LABS 262.7 7% DR REDDYS LABS 296.3 1%
10 GLENMARK PHARMA 262.5 10 % MICRO LABS* 231.2 7%
11 ARISTO PHARMA* 244.1 24 % ALKEM* 217.5 20 %
12 USV 237.6 22 % GLENMARK PHARMA 214.8 11 %
13 GLAXOSMITHKLINE* 237.3 14 % FOURRTS INDIA 214.2 13 %
14 MICRO LABS* 219.7 -8 % USV 197.0 6%
15 JB PHARMA* 179.7 17 % PFIZER* 184.4 -13 %
16 MANKIND 171.0 19 % ERIS LIFESCIENCES* 167.9 4%
17 SANOFI* 164.1 -2 % INTAS PHARMA* 166.1 13 %
18 PFIZER* 153.9 -3 % ARISTO PHARMA* 159.2 27 %
19 ERIS LIFESCIENCES* 146.4 13 % EMCURE* 153.4 14 %
20 IPCA LABS 134.0 9% SANOFI* 153.2 2%
Telangana Chennai
Rank Company Value'Cr Growth % Company Value'Cr Growth %
1 ABBOTT* 764.9 10 % SUN* 390.3 11 %
2 SUN* 694.3 9% ABBOTT* 287.7 8%
3 INTAS PHARMA* 475.9 24 % CIPLA 174.0 -1 %
4 CIPLA 423.0 17 % LUPIN LIMITED 173.9 13 %
5 MANKIND 399.2 15 % INTAS PHARMA* 154.7 20 %
6 ALKEM* 377.8 34 % USV 150.0 7%
7 LUPIN LIMITED 376.2 13 % DR REDDYS LABS 138.8 -9 %
8 USV 335.6 11 % TORRENT PHARMA* 128.1 5%
9 DR REDDYS LABS 321.2 23 % GLENMARK PHARMA 127.1 20 %
10 GLENMARK PHARMA 316.7 7% MANKIND 126.9 8%
11 TORRENT PHARMA* 251.5 17 % MICRO LABS* 112.5 17 %
12 ARISTO PHARMA* 240.1 27 % ALKEM* 111.4 20 %
13 MACLEODS PHARMA 232.5 32 % IPCA LABS 108.4 21 %
14 PFIZER* 230.0 14 % SANOFI* 104.5 6%
15 ZYDUS CADILA* 209.4 16 % ZYDUS CADILA* 102.8 12 %
16 EMCURE* 204.1 22 % GLAXOSMITHKLINE* 96.7 3%
17 GLAXOSMITHKLINE* 201.2 -2 % LA RENON HEALTHCA. 94.4 57 %
18 SANOFI* 199.1 -7 % EMCURE* 90.9 -37 %
19 IPCA LABS 195.0 28 % PFIZER* 72.7 -7 %
20 HETERO HEALTHCARE* 156.0 151 % ERIS LIFESCIENCES* 67.8 8%

Source: IQVIA TSA Dataset June'2023 16

South Zone Top Brands- MAT
June’23
Andhra Pradesh Karnataka Kerala
Ran
k Brand Compan Value Growt Compan Value Growt Value Growth
Brand Brand Company
y 'Cr h% y 'Cr h% 'Cr %
GLYCOMET-
1 USV 55.3 20 % GLYCOMET-GP USV 106.7 18 % MIXTARD ABT 108.8 1%
GP
2 MIXTARD ABT 49.0 -2 % MIXTARD ABT 86.9 11 % FORACORT CPL 76.9 32 %
3 GEMER SPI 40.8 1 % DOLO MRB 58.7 -1 % CILACAR JBH 68.5 15 %
4 ZINCOVIT APX 35.0 0 % ULTRACET JAN 55.6 42 % THYRONORM ABT 62.9 14 %
5 DOLO MRB 34.4 17 % THYRONORM ABT 53.1 28 % LANTUS S.A 51.4 2%
6 PANTOP ATP 33.5 7 % AUGMENTIN GSK 44.4 24 % GLYCOMET-GP USV 51.2 30 %
7 MONOCEF ATP 31.4 17 % VOLINI RG. 42.8 5 % MOXCLAV RXC 50.8 43 %
8 THYRONORM ABT 28.1 13 % NOVOMIX ABT 38.1 1 % SEROFLO CPL 49.6 -5 %
9 MYFAIR ZEE 23.9 18 % LEVIPIL SPI 38.0 10 % PANTOCID SPI 49.3 13 %
10 ROSUVAS RBY 22.7 15 % RYZODEG ABT 35.8 54 % AUGMENTIN GSK 48.1 49 %
11 ZORYL-M IN9 22.4 7 % GLYCOMET TRIO USV 34.7 33 % SHELCAL TNT 45.6 6%
ONE TOUCH
12 MONOCEF-SB ATP 21.4 27 % ECOSPRIN-AV USV 34.0 31 % J&J 40.8 13 %
SELECT
13 FORACORT CPL 21.1 10 % FORACORT CPL 33.5 19 % PANTOP ATP 39.2 24 %
14 PANTOP-D ATP 20.1 20 % LANTUS S.A 31.0 3 % ROSUVAS RBY 37.4 21 %
15 TELMA-H GMK 19.1 7 % CILACAR JBH 30.1 61 % CONCOR MSE 36.1 36 %
16 BUDECORT CPL 19.0 43 % SINAREST CAU 29.5 20 % DOLO MRB 33.4 -2 %
17 MOXIKIND-CV MA& 18.8 43 % DUPHASTON SVY 28.9 8 % NOVOMIX ABT 33.3 -3 %
18 DUOLIN CPL 18.7 6 % PAN A.K 28.1 16 % JANUMET MSD 31.1 -16 %
19 TRASTUREL REL. 18.2 -2 % MOXIKIND-CV MA& 28.1 26 % TELMA GMK 30.8 7%
20 AUGMENTIN GSK 18.1 20 % BETADINE WMC 27.7 30 % NEBICARD TNT 29.5 4%

Tamilnadu Telangana Chennai

Rank
Brand Company Value'Cr Growth % Brand Company Value'Cr Growth % Brand Company Value'Cr Growth %

1 MIXTARD ABT 93.4 6% TAFFIC HETERO 84.1 1,780 % MIXTARD ABT 31.2 11 %

2 GLYCOMET-GP USV 46.8 9% MAGNEX PFZ 83.7 31 % GLYCOMET-GP USV 29.2 4%

3 AUGMENTIN GSK 46.2 36 % MIXTARD ABT 80.9 -6 % LANTUS S.A 23.2 -4 %

4 FORACORT CPL 45.1 1% GLYCOMET-GP USV 80.7 3% PAN A.K 22.8 10 %

5 T-BACT GSK 44.6 25 % THYRONORM ABT 59.6 9% JANUMET MSD 21.3 6%

6 GEMER SPI 43.6 13 % CEFTUM GSK 51.8 -33 % NOVOMIX ABT 21.0 1%
RENERVE
7 ELS 43.2 11 % NOVOMIX ABT 50.4 -8 % DUPHASTON SVY 20.5 38 %
PLUS
8 LEVIPIL SPI 42.3 15 % TELMA-H GMK 49.5 12 % ERBITUX MERCK 20.4 182 %

9 ROSUVAS RBY 41.7 25 % DOLO MRB 48.4 46 % RYZODEG ABT 20.2 20 %

10 TEDIBAR TNT 40.3 14 % IMMUNOREL REL 45.4 -7 % TRASTUREL REL. 20.0 57 %

11 JANUMET MSD 36.4 -8 % MEROPLAN A1H 44.0 42 % AZITHRAL AMB 19.8 12 %

12 ZINCOVIT APX 35.7 6% TELMA GMK 43.1 16 % FOLISURGE IN9 19.8 53 %

13 ELTROXIN GSK 31.9 9% RYZODEG ABT 41.9 34 % PREVENAR-13 WYE 19.0 -29 %

14 VOLINI RG. 31.8 -1 % MERONEM PFIZER* 34.8 -3 % JARDIANCE B.I 15.4 -16 %
GLYCOMET
15 DOLO MRB 31.6 11 % USV 33.4 21 % AUGMENTIN GSK 15.2 20 %
TRIO
16 ASTHALIN CPL 29.5 25 % LANTUS S.A 32.6 -23 % RENERVE PLUS ELS 14.5 30 %

17 SUSTEN SPI 29.5 -13 % CLAVAM A.K 32.5 51 % ALLEGRA S.A 14.3 33 %

18 AZITHRAL AMB 29.3 20 % ZORYL-M IN9 30.7 5% TELMA GMK 12.5 16 %

19 VERTIN SVY 29.0 15 % ALBUREL REL 30.6 78 % PAN-D A.K 12.0 12 %

20 NOVOMIX ABT 28.2 -20 % LEVIPIL SPI 30.2 -3 % ROSUVAS RBY 11.9 -6 %

Source: IQVIA TSA Dataset June'2023 17